https://pubmed.ncbi.nlm.nih.gov/38116416
Scientists have synthesized seven new Teixobactin analogues with a total lactam ring and found that certain compounds containing Nle11 showed promising antimicrobial activity against resistant pathogens.
https://pubmed.ncbi.nlm.nih.gov/38116416
Scientists have synthesized seven new Teixobactin analogues with a total lactam ring and found that certain compounds containing Nle11 showed promising antimicrobial activity against resistant pathogens.
https://pubmed.ncbi.nlm.nih.gov/38116415
A specially designed, neutral flavin-triphenylamine probe shows potential as an alternative to existing mitochondrial trackers, offering advantages like long-term tracking, faster internalization, and strong emission under hypoxia conditions.
https://pubmed.ncbi.nlm.nih.gov/38116413
Researchers have identified new N-biphenyl pyrrolinones and N-dibenzofurans as potent LIN28 inhibitors, challenging the belief that a salicylic acid moiety is essential for activity, and potentially improving membrane permeability and reducing toxicity.
https://pubmed.ncbi.nlm.nih.gov/38116412
The study identifies key kinases that maintain the stability of the oncogenic MYCN protein in neuroblastoma cells, and demonstrates the effectiveness of targeting these kinases to degrade MYCN and induce cell death.
https://pubmed.ncbi.nlm.nih.gov/38116411
Disulfiram, a drug used for alcohol-aversion therapy, has been found to be effectively repurposed for various diseases in vitro, but its limited presence and activity in the body raise concerns about its misleading use in research.
https://pubmed.ncbi.nlm.nih.gov/38116410
This study describes a new method for synthesizing monodeuterated enaminones with high isotopic fidelity and efficient use of deuterium, which may help address the unexpected oxidation of nitrogenous heterocycles by aldehyde oxidase.
https://pubmed.ncbi.nlm.nih.gov/38116409
A new small molecule, indazole analogue 16, has shown potential as a starting point for developing a therapy for castration-resistant prostate cancer, as it inhibits the androgen receptor N-terminal domain and has favorable physical and chemical properties.
https://pubmed.ncbi.nlm.nih.gov/38116408
This abstract describes the discovery and potential therapeutic use of novel pyrido[3,2-d]pyrimidines as HPK1 inhibitors for treating cancer and inflammatory and autoimmune diseases.